Cover Image
市場調查報告書

遺傳性共濟失調症:開發中產品分析

Friedreich Ataxia - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 219741
出版日期 內容資訊 英文 85 Pages
訂單完成後即時交付
價格
Back to Top
遺傳性共濟失調症:開發中產品分析 Friedreich Ataxia - Pipeline Review, H1 2017
出版日期: 2017年04月11日 內容資訊: 英文 85 Pages
簡介

遺傳性共濟失調症是影響神經系統和心臟的遺傳性疾病,由於遺傳性缺陷基因所引起。症狀有運動失調、虛弱、痙攣、感覺障礙、骨骼異常、心臟障礙、糖尿病等。

本報告提供全球遺傳性共濟失調症治療用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

遺傳性共濟失調症概要

治療藥的開發

  • 遺傳性共濟失調症開發中產品:概要
  • 各企業開發中的治療藥
  • 大學/研究機關研究中的治療藥
  • 遺傳性共濟失調症:開發中產品一覽(各企業)
  • 遺傳性共濟失調症:研究中產品一覽(各大學/研究機關)

遺傳性共濟失調症:治療藥的評估

  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

遺傳性共濟失調症的開發作的企業

  • Adverum Biotechnologies Inc
  • BioMarin Pharmaceutical Inc.
  • Biovista Inc.
  • Cardero Therapeutics Inc
  • Catabasis Pharmaceuticals, Inc.
  • Forward Pharma A/S
  • Ixchel Pharma LLC
  • Pfizer Inc
  • ProQR Therapeutics NV
  • RaNA Therapeutics Inc
  • Reata Pharmaceuticals Inc
  • Retrotope Inc
  • Shire Plc
  • STATegics Inc
  • Voyager Therapeutics Inc

藥物簡介

遺傳性共濟失調症:開發暫停的產品

遺傳性共濟失調症:開發中止的產品

遺傳性共濟失調症相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9169IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Friedreich Ataxia - Pipeline Review, H1 2017, provides an overview of the Friedreich Ataxia (Central Nervous System) pipeline landscape.

Friedreich's ataxia (FA) is a neuromuscular disease that mainly affects the nervous system and the heart. FA is a hereditary disease, caused by a defective gene that can be passed down through a family. Signs and symptoms include ataxia, weakness and spasticity, sensory impairment, skeletal abnormalities, cardiac difficulties and diabetes.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Friedreich Ataxia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Friedreich Ataxia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Friedreich Ataxia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Friedreich Ataxia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 2, 13 and 3 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 1 and 2 molecules, respectively.

Friedreich Ataxia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Friedreich Ataxia (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Friedreich Ataxia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Friedreich Ataxia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Friedreich Ataxia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Friedreich Ataxia (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Friedreich Ataxia (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Friedreich Ataxia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Friedreich Ataxia - Overview
    • Friedreich Ataxia - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Friedreich Ataxia - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Friedreich Ataxia - Companies Involved in Therapeutics Development
    • Adverum Biotechnologies Inc
    • BioMarin Pharmaceutical Inc
    • Biovista Inc
    • Cardero Therapeutics Inc
    • Catabasis Pharmaceuticals Inc
    • Edison Pharmaceuticals Inc
    • Forward Pharma A/S
    • Ixchel Pharma LLC
    • Pfizer Inc
    • ProQR Therapeutics NV
    • RaNA Therapeutics Inc
    • Reata Pharmaceuticals Inc
    • Retrotope Inc
    • Shire Plc
    • STATegics Inc
    • Voyager Therapeutics Inc
  • Friedreich Ataxia - Drug Profiles
    • ADVM-063 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AGIL-FA - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BVA-202 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BVA-203 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CAT-4001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cell Therapy for Central Nervous System and Neurodegenerative Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CTI-1601 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dextro epicatechin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dimethyl fumarate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Frataxin for Friedreich's Ataxia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Frataxin for Friedreich's Ataxia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Frataxin for Friedrich's Ataxia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • interferon gamma-1b - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IXC-105 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JOT-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oligonucleotide to Activate Frataxin for Friedreich's Ataxia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omaveloxolone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • QRX-604 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein 1 to Replace FXN for Friedreich Ataxia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RG-3250 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RT-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RT-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SHP-622 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate Frataxin for Friedreich Ataxia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • STSE-15 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vatiquinone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VYFXN-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Friedreich Ataxia - Dormant Projects
  • Friedreich Ataxia - Discontinued Products
  • Friedreich Ataxia - Product Development Milestones
    • Featured News & Press Releases
      • Nov 17, 2016: Catabasis Pharmaceuticals Provides Update on Rare Disease Program CAT-4001 at Investor Day
      • Aug 02, 2016: Agilis Biotherapeutics Announces FDA Orphan Drug Designation for the Treatment of Friedreich's Ataxia
      • Jan 19, 2016: FARA Announces Catabasis Pharmaceuticals as the Recipient of the Kyle Bryant Translational Research Award to Evaluate CAT-4001 as a Potential Therapy for Friedreich's Ataxia
      • Aug 05, 2015: Key Patent Granted For AAVLife's Gene-Therapy Program to Treat Cardiomyopathy in Friedreich's Ataxia
      • Mar 24, 2015: Catabasis Pharmaceuticals to Present at International Ataxia Research Conference
      • Mar 17, 2014: FDA Awards Fast Track Status to Edison Pharmaceuticals' EPI-743 for Friedreich's Ataxia
      • Feb 04, 2014: FDA Grants Edison Pharmaceuticals' EPI-743 Orphan Status for Friedreich's Ataxia
      • Nov 04, 2013: Edison Pharmaceuticals, FARA, and USF Announce Initiation of EPI-743 Phase 2 Friedreich's Ataxia Clinical Trial in Adults with Point Mutations
      • Jan 07, 2013: Edison Pharma Initiates Phase IIb Clinical Trial Of EPI-743 In Friedreich Ataxia
      • Aug 01, 2012: Intellect Neurosciences Receives New Patent Allowance For OX1
      • Aug 02, 2011: STATegics, Inc. Announces a Grant from Friedreich's Ataxia Research Alliance to Support Its Program to Develop Small Molecule Mimetics of Erythropoietin for the Treatment of Friedreich's Ataxia
      • Apr 12, 2011: Intellect Neurosciences Files Orphan Drug Application In US For OX1 In Friedreich's Ataxia
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Friedreich Ataxia, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Friedreich Ataxia - Pipeline by Adverum Biotechnologies Inc, H1 2017
  • Friedreich Ataxia - Pipeline by BioMarin Pharmaceutical Inc, H1 2017
  • Friedreich Ataxia - Pipeline by Biovista Inc, H1 2017
  • Friedreich Ataxia - Pipeline by Cardero Therapeutics Inc, H1 2017
  • Friedreich Ataxia - Pipeline by Catabasis Pharmaceuticals Inc, H1 2017
  • Friedreich Ataxia - Pipeline by Edison Pharmaceuticals Inc, H1 2017
  • Friedreich Ataxia - Pipeline by Forward Pharma A/S, H1 2017
  • Friedreich Ataxia - Pipeline by Ixchel Pharma LLC, H1 2017
  • Friedreich Ataxia - Pipeline by Pfizer Inc, H1 2017
  • Friedreich Ataxia - Pipeline by ProQR Therapeutics NV, H1 2017
  • Friedreich Ataxia - Pipeline by RaNA Therapeutics Inc, H1 2017
  • Friedreich Ataxia - Pipeline by Reata Pharmaceuticals Inc, H1 2017
  • Friedreich Ataxia - Pipeline by Retrotope Inc, H1 2017
  • Friedreich Ataxia - Pipeline by Shire Plc, H1 2017
  • Friedreich Ataxia - Pipeline by STATegics Inc, H1 2017
  • Friedreich Ataxia - Pipeline by Voyager Therapeutics Inc, H1 2017
  • Friedreich Ataxia - Dormant Projects, H1 2017
  • Friedreich Ataxia - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Friedreich Ataxia, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top